Merus N V (MRUS) Return on Equity ROE from the third quarter 2025 to third quarter 2024 and annually, average high and low, overall ranking from Sep 30 2025 to Sep 30 2024 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Merus N v   (NASDAQ: MRUS)

Merus N V 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Merus N V in the third quarter 2025?
Merus N V recorded a cumulative net loss of $-381 million during 12 months ending in the third quarter 2025, resulting in a negative return on equity (ROE) of -53.29%.

Within the Major Pharmaceutical Preparations industry 170 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the second quarter 2025 from 2831 to 3061.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter		 (Sep 30 2024)
III. Quarter
Y / Y Equity Change 10.19 % 12.72 % 70.59 % 81.83 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -381 -386 -277 -215 -245
Return On Equity (TTM) -53.29 % -55.29 % -41.18 % -35.19 % -45.38 %
MRUS's Total Ranking # 3061 # 2831 # 2388 # 1970 # 911
Equity (TTM) in Millions 775 842 596 648 703
Seq. Equity Change -7.94 % 41.2 % -8 % -7.87 % -5.83 %
Seq. Net Income Change - - - - -

Back to MRUS Management Effectiveness >> MRUS's 5 Years Annual ROE >> Compare MRUS ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 171
Sector # 406
Overall # 3061

Return On Equity Statistics
High Average Low
-18.81 %
-46.7 %
-85.16 %
(Jun 30 2022)   (Dec 31 2020)





MRUS Annual Return On Equity (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020
Total Equity in Millions 648 356 247 316 102
Y / Y Equity Change 81.83 % 44.24 % -21.87 % 209.2 % -22.12 %
Net Income in Millions -215 -155 -131 -67 -86
Y / Y Net Income Change - - - - -
Return On Equity -33.23 % -43.48 % -53.1 % -21.13 % -83.62 %

Back to MRUS Management Effectiveness >> MRUS's 5 Years Annual ROE >> Compare MRUS ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
MRUS's' Return on Equity at Yahoo Finance
MRUS's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for MRUS's Competitors
Subscribers only: Roe for Merus N V 's Suppliers
Subscribers only: Return On Equity for MRUS's Customers




Companies with similar Return On Equity at Sep 30 2025, within Healthcare Sector ROE

Date modified: 2026-09-18T13:11:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.